


PHARMACEUTICAL 2022

Syndax Pharmaceuticals Inc Rank 19 of 475

Syndax 🌮







RealRate

PHARMACEUTICAL 2022



Syndax Pharmaceuticals Inc Rank 19 of 475

The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 286% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 1.5% points.

The company's Economic Capital Ratio, given in the ranking table, is 224%, being 501% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	448,396
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,683
Liabilities, Non-Current	20,606
Other Assets	983
Other Compr. Net Income	49
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,294
Property and Equipment	278
Research and Development	88,248
Revenues	139,709
Selling, General and Administrative Expense	25,241

Output Variable	Value in 1000 USD
Assets	449,657
Liabilities	41,289
Expenses	113,489
Stockholders Equity	408,368
Net Income	24,926
Comprehensive Net Income	24,950
Economic Capital Ratio	224%

